Article
Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population.
Lung cancer (Amsterdam, Netherlands) - 1 Mar 2020
Zeng Liang, Xiao Lili, Jiang Wenjuan, Yang Haiyan, Hu Dandan, Xia Chen, Li Yizhi, Zhou Chunhua, Xiong Yi, Liu Li, Liao Dehua, Guan Rui, Li Kunyan, Wang Jing, Zhang Yongchang, Yang Nong, Mansfield Aaron S
Abstract excerpt
OBJECTIVES: We aimed to investigate the clinical efficacy of EGFR tyrosine kinase inhibitor (TKI, T) plus bevacizumab (an antiangiogenic therapy, A) in a real-world population and to provide insights into their mechanism of resistance. METHODS: This study included 256 NSCLC patients harboring EGFR sensitizing mutations (EGFR 19del and L858R) who underwent nextgeneration sequencing (NGS) with 168-gene panel prior...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.